Readystate Asset Management LP Buys Shares of 188,154 Catalent, Inc. (NYSE:CTLT)

Readystate Asset Management LP acquired a new stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 188,154 shares of the company's stock, valued at approximately $11,396,000. Readystate Asset Management LP owned approximately 0.10% of Catalent as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Brooklyn Investment Group acquired a new stake in shares of Catalent in the third quarter worth $31,000. Sentry Investment Management LLC acquired a new stake in shares of Catalent in the third quarter worth $53,000. Longfellow Investment Management Co. LLC lifted its stake in shares of Catalent by 45.7% in the second quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company's stock worth $55,000 after buying an additional 305 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company's stock worth $58,000 after buying an additional 212 shares during the last quarter. Finally, Thurston Springer Miller Herd & Titak Inc. lifted its stake in shares of Catalent by 57.5% in the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company's stock worth $72,000 after buying an additional 431 shares during the last quarter.

Catalent Stock Performance

Catalent stock traded up $0.14 on Thursday, hitting $61.98. The company's stock had a trading volume of 1,723,756 shares, compared to its average volume of 2,038,744. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. The company has a fifty day moving average price of $60.00 and a 200-day moving average price of $58.62. Catalent, Inc. has a one year low of $36.74 and a one year high of $62.20.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same period in the previous year, the company posted ($0.10) EPS. The firm's revenue for the quarter was up 4.2% compared to the same quarter last year. Equities analysts predict that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Transactions at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now owns 10,835 shares of the company's stock, valued at $646,849.50. This represents a 20.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the sale, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,114 shares of company stock valued at $305,931. 0.31% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on CTLT shares. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. William Blair reiterated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com upgraded shares of Catalent from a "sell" rating to a "hold" rating in a research note on Monday. Finally, Robert W. Baird reiterated a "neutral" rating and set a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. Eight equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.